Lifecore (LFCR) Biomedical announced that it has signed an agreement with a leading global pharmaceutical company. Under the terms of the agreement, Lifecore will transfer the commercial manufacturing for a leading injectable pharmaceutical product from the current manufacturer to Lifecore’s facilities. Upon completion of the transfer and satisfaction of all regulatory requirements, Lifecore will be the commercial supplier of choice for the product. This is the second agreement that Lifecore has signed with the same multinational organization in recent months, highlighting the company’s growing reputation for technical excellence, quality, and reliability in sterile injectables.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore, PolyPeptide collab to offer peptide manufacturing solution
- Lifecore Biomedical, Inc. (LFCR) Q1 Earnings Cheat Sheet
- Lifecore Biomedical Approves New Cash Incentive Plan
- Hold Rating for Lifecore Biomedical Amid Strategic Progress and High Leverage Concerns
- Lifecore files to sell $150M of common stock, warrants